Page 1 | Search Results | Blood | American Society of Hematology

1-9 of 9

Sort by

Sort Order Select

Journal Articles

V2 Trial: A Phase I Study of Venetoclax Combined with CPX-351 for Children, Adolescents and Young Adults with Relapsed or Refractory Acute Leukemia

Laura Agresta, MD, Maureen M O'Brien, MD, Kana Mizuno, PhD, Robin Norris, MD MS, MPH, Erin H. Breese, MD PhD, Christine L Phillips, MD, Karen Burns, MD, Benjamin Mizukawa, Lynn Lee, MD, Adam Lane, PhD, Robert B. Lorsbach, MD PhD, Thomas D. Ryan, MD PhD, Pankaj B. Desai, PhD, Alexander A. Vinks, PharmD, PhD, H. Leighton Grimes, PhD, John P Perentesis, Michael J. Absalon, MD PhD

Blood (2019) 134 (Supplement_1): 3830.

https://doi.org/10.1182/blood-2019-121514

Published: 2019

Journal Articles

Hydroxyurea Pharmacokinetic Profiles in Children Treated for Extreme Thrombocytosis after Total Pancreatectomy with Islet Cell Autotransplant Demonstrate Poor Absorption

Alexander A Boucher, MD, Min Dong, PhD, Anu Marahatta, PhD, Adriane Hausfeld, Thad A. Howard, MS, Jaimie D Nathan, MD, Alexander A. Vinks, PharmD, PhD FCP, Patrick T. McGann, MD, Russell E. Ware, MD PhD, Lori Luchtman-Jones, MD

Blood (2019) 134 (Supplement_1): 4893.

https://doi.org/10.1182/blood-2019-127378

Published: 2019

Journal Articles

Clinical and Laboratory Benefits of Early Initiation of Hydroxyurea with Pharmacokinetic Guided Dosing for Young Children with Sickle Cell Anemia

Patrick T. McGann, MD, Omar Niss, MD, Min Dong, PhD, Anu Marahatta, PhD, Tomoyuki Mizuno, PhD, Karen Kalinyak, MD, Theodosia A. Kalfa, MD PhD, Punam Malik, MD, Charles T. Quinn, MD, Russell E. Ware, MD PhD, Alexander A. Vinks, PharmD, PhD FCP

Blood (2018) 132 (Supplement 1): 507.

https://doi.org/10.1182/blood-2018-99-112909

Published: 2018

Journal Articles

Hydroxyurea Exposure in Lactation—a Pharmacokinetics Study (HELPS)

Russell E. Ware, MD PhD, Anu Marahatta, PhD, Julie L Ware, MD MPH, Kathryn L McElhinney, BS, Min Dong, PhD, Alexander A. Vinks, PharmD, PhD FCP

Blood (2018) 132 (Supplement 1): 3677.

https://doi.org/10.1182/blood-2018-99-114142

Published: 2018

Journal Articles

Personalized Hydroxyurea Dosing to Reduce Time to MTD and Optimize the HbF Response: Results from the TREAT Study

Patrick T. McGann, MD MS, Omar Niss, MD, Min Dong, PhD, Anu Marahatta, PhD, Kathryn L McElhinney, BS, Thad A. Howard, MS, Tomoyuki Mizuno, PhD, Theodosia A. Kalfa, MD PhD, Karen Kalinyak, MD, Punam Malik, MD, Charles T. Quinn, MD MS, Russell E. Ware, MD PhD, Alexander A. Vinks, PharmD, PhD FCP

Blood (2017) 130 (Supplement 1): 615.

https://doi.org/10.1182/blood.V130.Suppl_1.615.615

Published: 2017

Journal Articles

Individualized Dosing of Hydroxyurea for Children with Sickle Cell Anemia Using a Population Pharmacokinetic-Based Model: The TREAT Study

Patrick T. McGann, MD MS, Min Dong, PhD, Anu Marahatta, PhD, Thad A. Howard, MS, Tomoyuki Mizuno, PhD, Karen A. Kalinyak, MD, Theodosia A. Kalfa, MD PhD, Punam Malik, MD, Omar Niss, MD, Charles T Quinn, MD, Russell E. Ware, MD PhD, Alexander A. Vinks, PharmD, PhD

Blood (2016) 128 (22): 3652.

https://doi.org/10.1182/blood.V128.22.3652.3652

Published: 2016

Journal Articles

Precision Dosing of Alemtuzumab: Population Pharmacokinetic Modeling in Pediatric Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Non-Malignant Diseases

Tsuyoshi Fukuda, PhD, Chie Emoto, PhD, Rebecca A Marsh, MD, Lisa Neumeier, BS, Alexander A. Vinks, PharmD, PhD, Parinda A Mehta, MD

Blood (2016) 128 (22): 2203.

https://doi.org/10.1182/blood.V128.22.2203.2203

Published: 2016

Journal Articles

Pharmacokinetics-Based Individualized Dosing Strategy to Predict Maximum Tolerated Dose of Hydroxyurea in Children with Sickle Cell Anemia

Patrick T. McGann, MD MS, Min Dong, PhD, Russell E. Ware, MD PhD, Alexander A Vinks, PharmD, PhD

Blood (2015) 126 (23): 982.

https://doi.org/10.1182/blood.V126.23.982.982

Published: 2015

Journal Articles

A Phase I Trial Of Zileuton In Sickle Cell Disease

Marthe-Sandrine Eiymo Mwa Mpollo, M.Sc., Maa-Ohui Quarmyne, MBChB, Omar Rayes, MD, Caryn S. Gonsalves, PhD, Laurie Vanderah, RN, Christina Canter, Johnson Haynes, Jr., MD, Claudia Fernanda Clavijio, MD, Christians Uwe, MD, PhD, Karen Kalinyak, MD, Clinton H. Joiner, MD, PhD, Alexander A. Vinks, PharmD, PhD, FCP, Punam Malik, MD

Blood (2013) 122 (21): 993.

https://doi.org/10.1182/blood.V122.21.993.993

Published: 2013

NARROW

V2 Trial: A Phase I Study of Venetoclax Combined with CPX-351 for Children, Adolescents and Young Adults with Relapsed or Refractory Acute Leukemia

Hydroxyurea Pharmacokinetic Profiles in Children Treated for Extreme Thrombocytosis after Total Pancreatectomy with Islet Cell Autotransplant Demonstrate Poor Absorption

Clinical and Laboratory Benefits of Early Initiation of Hydroxyurea with Pharmacokinetic Guided Dosing for Young Children with Sickle Cell Anemia

Hydroxyurea Exposure in Lactation—a Pharmacokinetics Study (HELPS)

Personalized Hydroxyurea Dosing to Reduce Time to MTD and Optimize the HbF Response: Results from the TREAT Study

Individualized Dosing of Hydroxyurea for Children with Sickle Cell Anemia Using a Population Pharmacokinetic-Based Model: The TREAT Study

Precision Dosing of Alemtuzumab: Population Pharmacokinetic Modeling in Pediatric Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Non-Malignant Diseases

Pharmacokinetics-Based Individualized Dosing Strategy to Predict Maximum Tolerated Dose of Hydroxyurea in Children with Sickle Cell Anemia

A Phase I Trial Of Zileuton In Sickle Cell Disease

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only